Parsing NJ Court's Rationale For Denying Lipitor Class Cert.
On June 6, a motion for summary judgment was granted in In re: Lipitor Antitrust Litigation, dismissing claims of a pay-for-delay settlement from Pfizer Inc., the manufacturer of Lipitor, to Ranbaxy....To view the full article, register now.
Already a subscriber? Click here to view full article